{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-126671","form_type":"8-K","ticker":"DBVT","cik":"0001613780","company_name":"DBV Technologies S.A.","filed_at":"2026-03-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:35.644613+00:00","generated_at":"2026-05-15T08:50:12.708023+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"DBV Technologies FY2025 net loss $147M; cash runway into Q2 2027; BLA on track H1 2026","bullets":["Net loss of $147M for FY2025, compared to $113.9M in FY2024; diluted EPS -$1.05.","Operating income $5.6M, up from $4.2M; R&D expenses rose to $116.7M due to pre-commercial inventory and clinical costs.","Cash and equivalents $194.2M as of Dec 31, 2025; additional $94M received Jan 2026; funding into Q2 2027.","BLA submission for VIASKIN Peanut Patch in children aged 4-7 years anticipated H1 2026; for toddlers 1-3 years H2 2026.","Appointed Kevin Trapp as CCO and James Briggs as CHRO; Philina Lee nominated to Board."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-126671","json":"https://secwatch.observer/filing/0001193125-26-126671.json","markdown":"https://secwatch.observer/filing/0001193125-26-126671.md","text":"https://secwatch.observer/filing/0001193125-26-126671.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/0001193125-26-126671-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/d113165d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T08:50:12.708023+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"4e61c83bb83401733c5c89207d732f2a049c313c","claim":"DBV Technologies S.A. reported the fiscal year ended December 31, 2025 results: net income $147.0 million, EPS $1.05.","evidence_excerpt":"Net loss was $147.0 million for the year ended December 31, 2025, compared to $113.9 million for the year ended December 31, 2024. Net loss per share (based on the weighted average number of shares outstanding over the period) was $1.05 and $1.17 for the year ended December 31, 2025 and 2024, respectively.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1613780/000119312526126671/0001193125-26-126671-index.htm","confidence":1.0,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2025"},{"label":"Net income","value":"$147.0 million"},{"label":"EPS","value":"$1.05"},{"label":"Result","value":"reported results"}]}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}